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JUPITER (Justification for the Use
of statins in Prevention: An Intervention
Trial Evaluating Rosuvastatin)*
Mark Hlatky, MD
Stanford, California
The most appropriate use of statins in primary prevention of
coronary artery disease has been difficult to establish. Clin-
ical trials have been conducted in various segments of the
population and suggest that statin treatment reduces the
relative risk of coronary events over follow-up periods of 2
to 5 years (1,2). But are the benefits of preventive treatment
worth the costs of long-term drug prescription? The answer
to this question depends on the balance between the
absolute risk reduction attained, the frequency and severity
of adverse events due to treatment, the cost of drug
treatment, and the potential for downstream cost savings by
preventing future coronary events. Cost-effectiveness anal-
ysis is a framework that gathers data on all these aspects of
the treatment decision and weighs them to assess the value
provided for the money spent.
See page 784
JUPITER (Justification for the Use of statins in Preven-
tion: An Intervention Trial Evaluating Rosuvastatin) was a
landmark randomized trial that compared rosuvastatin
treatment with placebo among individuals who did not have
coronary disease, but were at intermediate risk of developing
it (3). The 54% relative risk reduction in major cardiac
events (from 2.8% to 1.6% over 1.9 years of follow-up)
reported by JUPITER has elicited a great deal of commen-
tary (4–6), in large part because there are millions of
mericans who might become eligible for statin treatment
7). JUPITER did not include a formal economic analysis,
o the actual costs of the treatment strategies and their
ost-effectiveness cannot be evaluated on the basis of pri-
ary data from that trial. In this issue of the Journal,
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From Stanford University School of Medicine, Stanford, California. Dr. Hlatky has
reported that he has no relationships to disclose.houdhry et al. (8) report the results of an economic
imulation based on published and unpublished data from
he JUPITER trial.
The model of Choudhry et al. (8) projects the clinical
utcomes and costs of JUPITER patients (men 50 years
f age and women 60 years of age with low-density
ipoprotein cholesterol levels 130 mg/dl, elevated high-
ensitivity C-reactive protein [hs-CRP] [2.0 mg/l], and
aseline characteristics of the JUPITER trial population)
nder 2 management strategies: 1) treatment with rosuvas-
atin; or 2) no treatment. They assumed the risk reductions
eported by the JUPITER trial would continue for 15 years,
hen taper off over the subsequent 10 years. They also
ssumed that the cost of rosuvastatin would drop to $1 per
ay after 9 years of treatment, when generic versions should
ecome available. On the basis of these and other assump-
ions, they project the average JUPITER patient will have
7,900 higher lifetime costs and accrue an additional 0.31
uality-adjusted life years (QALYs), yielding an incremen-
al cost-effectiveness ratio of $25,200/QALY. By the stan-
ard benchmarks of economic evaluation, this is a reason-
ble return on the money spent on treatment.
The model of Choudhry et al. (8) does not really address
he cost-effectiveness of hs-CRP testing, but instead exam-
nes whether to treat with rosuvastatin after hs-CRP testing
as already been done. Although the strategies in their
odel are labeled “test and treat” and “no testing, no
reatment,” they did not examine the full array of options
eeded to evaluate an hs-CRP screening program, such as
he frequency of testing, the yield in different segments of
he population, or alternative methods to treat higher-risk
ubjects. Effectively, the model simply added the one-time
ost of hs-CRP testing ($19 per test, or $37.77 per positive
est), which is just 0.4% of the net treatment costs in the
odel, the bulk of which come from the cost of rosuvastatin
reatment. A comprehensive analysis of hs-CRP screening
s needed to inform policy decisions.
A key feature of any cost-effectiveness model is the
ystematic attempt to determine how much the results
hange when the model assumptions and parameters are
aried over a “reasonable range.” This key exercise (termed
sensitivity analysis) identifies whether the results change
rastically or only slightly under alternative assumptions and
hereby provide insight into the critical determinants of
conomic value. Not surprisingly, results of the model of the
ost-effectiveness of rosuvastatin treatment in JUPITER
ere sensitive to several parameters in the model, particu-
arly the degree of risk reduction from treatment, the
otential for adverse events, and the cost of rosuvastatin.
Clearly, the degree of risk reduction from rosuvastatin
ught to have a major effect on the cost-effectiveness of
reatment: If a treatment did not reduce risk, it would not be
orth paying for. The model of Choudhry et al. (8) was
ased only on the results of JUPITER, however, not the
otality of evidence about the effectiveness of statin treat-
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February 15, 2011:792–3 Cost-Effectiveness in the JUPITER Trialment for primary prevention. Their sensitivity analysis
tested only a narrow range of risk reduction, based only on
the statistical confidence limits of the JUPITER trial. It has
been widely noted that the early stopping of JUPITER may
have biased the observed risk reduction toward lower levels
(4,9), but the model did not account for this possibility.
Even more important than the level of risk reduction is how
long the risk reduction can be expected to last. Cost-
effectiveness analysis takes a lifetime perspective, and so it
matters whether a treatment will continue to work over the
long term. The problem is that few if any clinical trials
follow patients for more than a couple of years, so there are
simply no reliable data on long-term treatment efficacy.
Choudhry et al. (8) assumed that rosuvastatin would cut the
risk of cardiac events by more than 50% for a full 15 years
(and have some effect for up to 25 years), even though the
average follow-up in JUPITER was only 1.9 years. When
they ran the model under the alternative assumption that
the effect of rosuvastatin would last only 5 years, the
cost-effectiveness ratio almost tripled, rising to $62,100/
QALY from its initial value of $25,200/QALY. The results
of this sensitivity analysis show that the cost-effectiveness
ratio from JUPITER is highly leveraged on the assumption
of sustained, deep risk reductions, an assumption for which
we have little data.
Choudhry et al. (8) also showed that the cost-
effectiveness of rosuvastatin treatment depends on baseline
risk of developing coronary disease. Among JUPITER-
eligible individuals with a Framingham Risk Score 10%,
he cost-effectiveness of treatment was $14,200/QALY, but
or those with a Framingham Risk Score10%, it was more
han 4-fold higher ($55,000/QALY). This result is consis-
ent with other models of statins for primary prevention
10,11). Simply put, the cost of drug treatment is the same
or all patients, but the absolute benefits are much lower in
ow-risk individuals, so cost-effectiveness becomes much
ess favorable as baseline risk is lowered.
The results of this cost-effectiveness analysis were also
ighly sensitive to model assumptions about adverse effects.
he base case assumed that all individuals would feel
ompletely well while taking rosuvastatin, without any
nnoying side effects or qualms about taking the drug every
ay for the rest of their lives. If, however, patients taking
osuvastatin had just a 2% decrement in their well-being,
he cost-effectiveness ratio soared to more than $62,600 per
ALY. This result implies that even small levels of adverse
ffects from treating healthy individuals will greatly affect
he cost-effectiveness of preventive drug treatment. This is
ecause the benefits of treatment are small in absolute terms
nd occur years in the future and so can be offset by even
mall negative effects of treatment.
On the cost side, Choudhry et al. (8) made 2 assumptions
hat reduce the net cost impact of rosuvastatin treatment.
irst, they assumed the drug price would decrease from
3.63/day to off-patent levels ($1.00/day) after 8 years. My
ack-of-the-envelope calculation is that the cost-effectivenessratio would be at least $45,000/QALY if this assumption
weren’t made. Second, they omitted the added medical costs
from living longer as a result of statin treatment, even though
it is conventional to include such costs. That is a smaller effect,
but including these costs would also have made the cost-
effectiveness ratio less favorable.
It is essential to remember that a cost-effective therapy
actually costs more money, not less. Prevention rarely saves
money, despite the wishes of some that it did. It has been
estimated that between 6 million and 12 million patients
might begin statin treatment based on JUPITER results (7).
houdhry et al. (8) estimate that such treatment would
ncrease lifetime health care costs by $7,900 per person, even
fter factoring in generic rosuvastatin prices and later cost
aving from preventing heart disease. Putting these figures
ogether implies it would cost between $50 billion and $95
illion to extend rosuvastatin therapy to JUPITER-eligible
atients in the U.S. Are we convinced this is the best use of
hese health care dollars?
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